Eyegene Inc.

Cheiljedang Corp.

Yang Je Cho

Jin Wook Jang

Na Gyong Lee

Doo Sik Kim

Won Il Yoo

Dong Hyun Lee

Sung Ho Lee

Hyeong Joon Lim

Shin Ae Park

Kwangsung Kim

Bo Young Ahn

Hye Ran Park

Na-Gyong Lee

Young Gi Kim

Je Hak Kim

Hyun Su Kim

Dong Eok Lee

Sun Pyo Hong

Dal Hyun Kim

Kwang Sung Kim

Wang Don Yoo

Kyoung Chul Ko

Won Ii Yoo

Kyung Sul Kim

Oh Woong Kwon

Wan Je Park

Ree An Yoo

Nam Joong Lee

Kap Soo Noh

Suk Hoon Ha

The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.

Immune modulator and vaccine composition containing the same

The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.

Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same

The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting ofantigen,antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (type b) antigen,antigen,antigen,antigen,antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.

Vaccine for inducing an improved immune reaction

The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis.

Pharmaceutical composition for preventing or treating arteriosclerosis

The present invention relates to immune stimulating composition comprising methylated bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.

Immune stimulating composition comprising bacterial chromosomal DNA fragments having methylated CpG sequences and non-toxic lipopolysaccharides

Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.

Composition for treating retinopathy or glaucoma comprising thrombin derived peptides

The present invention relates to immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysacchararides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.

Immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides

The present invention relates to a vaccine prepared from an attenuated Pseudomonas aeruginosa strains which are obtained by isolating Pseudomonas aeruginosa in a pure state according to the Fisher-Devlin immunotype and then repeatedly purifying the isolated strain, particularly CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031), CFCPA 40057 (KCCM 10032), CFCPA 50243 (KCCM 10033), CFCPA 60534 (KCCM 10034) and CFCPA 70018 (KCCM 10035) strains. In addition, the present invention relates to a process for preparing the vaccine for immunization against Pseudomonas aeruginosa infection which contains cell wall proteins having molecular weights ranging from 10,000 to 100,000. The cell wall protein component of the attenuated strain is non-pathogenic and safe, and exhibits excellent antibody formation capacity and is useful for preparation of a vaccine and therapeutic agent. The cell wall proteins exhibit an excellent cross-protective efficacy for various Pseudomonas aeruginosa strains and a superior antibody inducing property.

Process for preparing a vaccine against pseudomonas aeruginosa using

Growing community of inventors

Seoul, South Korea

Yang Je Cho